# A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

> **NCT00845039** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 4 (actual)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab
- **DRUG:** Irinotecan
- **BIOLOGICAL:** IMC-A12 (cixutumumab)

## Key facts

- **NCT ID:** NCT00845039
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study terminated early 22Feb2010 with only 4 participants due to business reasons.
- **Last updated:** 2018-07-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845039, "A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00845039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*